1.Antibiotics-associated Diarrhea and Other Gastrointestinal Abnormal Responses Regarding Helicobacter pylori Eradication.
Soon Beom KWON ; Kook Lae LEE ; Joon Suk KIM ; Jae Kyung LEE ; Won KIM ; Yong Jin JUNG ; Ji Bong JEONG ; Ji Won KIM ; Byeong Gwan KIM
The Korean Journal of Gastroenterology 2010;56(4):229-235
BACKGROUND/AIMS: Helicobacter pylori (H. pylori) is closely related with a wide range of gastrointestinal disease. One-week triple therapy is currently considered as the golden standard for the treatment of H. pylori infection. However, gastrointestinal abnormal responses are major pitfalls in such regimen. The aim of this study was to identify symptoms, frequency and severity of antibiotics-associated gastrointestinal abnormal responses during H. pylori eradication therapy. METHODS: Sixty-seven patients with H. pylori infection between September 2005 and March 2006 were included. After 1 week of H. pylori eradication triple therapy (rabeprazol 10 mg, clarithromycin 500 mg, amoxicillin 1 g bid), we evaluated gastrointestinal abnormal responses (diarrhea, bloating, constipation, abdominal pain, borborygmus, flatulence, stool frequency, belching, and nausea) and severities every week for 4 weeks. RESULTS: The incidence of diarrhea was the highest in week 1, which was 41.28% (n=28) and the lowest in week 4, which was 9.52% (n=6) and decreased from week 1 to week 4 with statistical significance (p<0.0001). The most common gastrointestinal abnormal responses were associated with flatulence in week 1 (n=21, 31.34%), week 2 (n=21, 33.33%) and abdominal distention in week 3 (n=16, 25.40%), week 4 (n=15, 23.81%). Most of gastrointestinal abnormal responses were mild, and the most common symptom with higher than moderate grade was abdominal pain (n=4, 40.00%) in week 1. Alcohol consumption and coexisting medical illness were not associated with diarrhea (p=0.0852, 0.9009 respectively). CONCLUSIONS: H. pylori eradication therapy is commonly associated with antibiotics-associated gastrointestinal abnormal responses, which may result in antibiotics intolerance and H. pylori eradication failure. Even though those symptoms are not so severe, we have to consider the gastrointestinal abnormal responses associated with H. pylori eradication, especially diarrhea.
Abdominal Pain/chemically induced
;
Adult
;
Alcohol Drinking
;
Anti-Bacterial Agents/*adverse effects/therapeutic use
;
Diarrhea/*chemically induced
;
Female
;
Flatulence/chemically induced/etiology
;
Gastrointestinal Diseases/*chemically induced
;
Helicobacter Infections/*drug therapy
;
*Helicobacter pylori
;
Humans
;
Male
;
Middle Aged
;
Young Adult
2.The safety of tadalafil in the treatment of erectile dysfunction.
National Journal of Andrology 2007;13(8):762-764
The cyclic nucleotide (cGMP) signalling pathway mediates the smooth-muscle relaxing effects of nitric oxide necessary for normal erectile function. Down-regulation of this pathway is the pathophysiological pivot of many forms of erectile dysfunction (ED) and leads to the development of some chronic diseases, such as hypertension and type 2 diabetes mellitus. Therefore, selective inhibition of the enzyme that catalyses the degradation of cGMP promotes erectile responses to sexual stimulation. Recently, a new phosphodiesterase type 5 (PDE-5) inhibitor tadalafil has emerged, which has a prolonged half-life. Here is a review of recent studies on the safety of tadalafil in the treatment of ED.
Back Pain
;
chemically induced
;
Carbolines
;
adverse effects
;
therapeutic use
;
Erectile Dysfunction
;
drug therapy
;
Headache
;
chemically induced
;
Humans
;
Male
;
Phosphodiesterase Inhibitors
;
adverse effects
;
therapeutic use
;
Tadalafil
3.Acute Pancreatitis Induced by Methimazole Treatment in a 51-Year-Old Korean Man: A Case Report.
Jung Hwa JUNG ; Jong Ryeal HAHM ; Jaehoon JUNG ; Soo Kyoung KIM ; Sungsu KIM ; Kyong Young KIM ; Bo Ra KIM ; Hong Jun KIM ; Yi Yeong JEONG ; Sun Joo KIM
Journal of Korean Medical Science 2014;29(8):1170-1173
Methimazole (MMI)-induced acute pancreatitis is very rare but severe adverse reaction. A 51-yr-old male developed a high fever, chills, and abdominal pain, two weeks after commencement on MMI for the treatment of Graves' disease. There was no evidence of agranulocytosis, and fever subsided soon after stopping MMI treatment. However, 5 hr after taking an additional dose of MMI, abdominal pain and fever developed again. His symptoms, biochemical, and imaging studies were compatible with acute pancreatitis. After withdrawal of MMI, he showed clinical improvement. This is the first case of MMI-induced acute pancreatitis in Korea. Clinicians should be aware of the rare but possible MMI-induced pancreatitis in patients complaining of fever and abdominal pain.
Abdominal Pain/*chemically induced/diagnosis
;
Acute Disease
;
Diagnosis, Differential
;
Fever of Unknown Origin/*chemically induced/diagnosis
;
Graves Disease/*drug therapy
;
Humans
;
Male
;
Methimazole/*adverse effects/*therapeutic use
;
Middle Aged
;
Pancreatitis/*chemically induced/diagnosis
;
Treatment Outcome
4.Acute Pancreatitis Induced by Methimazole Treatment in a 51-Year-Old Korean Man: A Case Report.
Jung Hwa JUNG ; Jong Ryeal HAHM ; Jaehoon JUNG ; Soo Kyoung KIM ; Sungsu KIM ; Kyong Young KIM ; Bo Ra KIM ; Hong Jun KIM ; Yi Yeong JEONG ; Sun Joo KIM
Journal of Korean Medical Science 2014;29(8):1170-1173
Methimazole (MMI)-induced acute pancreatitis is very rare but severe adverse reaction. A 51-yr-old male developed a high fever, chills, and abdominal pain, two weeks after commencement on MMI for the treatment of Graves' disease. There was no evidence of agranulocytosis, and fever subsided soon after stopping MMI treatment. However, 5 hr after taking an additional dose of MMI, abdominal pain and fever developed again. His symptoms, biochemical, and imaging studies were compatible with acute pancreatitis. After withdrawal of MMI, he showed clinical improvement. This is the first case of MMI-induced acute pancreatitis in Korea. Clinicians should be aware of the rare but possible MMI-induced pancreatitis in patients complaining of fever and abdominal pain.
Abdominal Pain/*chemically induced/diagnosis
;
Acute Disease
;
Diagnosis, Differential
;
Fever of Unknown Origin/*chemically induced/diagnosis
;
Graves Disease/*drug therapy
;
Humans
;
Male
;
Methimazole/*adverse effects/*therapeutic use
;
Middle Aged
;
Pancreatitis/*chemically induced/diagnosis
;
Treatment Outcome
5.Clinical characteristics and related factors analysis of adrenal crisis occurred in children with primary nephrotic syndrome.
Na GUAN ; Hui Jie XIAO ; Bai Ge SU ; Xu Hui ZHONG ; Fang WANG ; Sai Nan ZHU
Chinese Journal of Pediatrics 2023;61(9):805-810
Objective: To investigate the clinical characteristics and related factors of corticosteroid induced adrenal crisis (AC) in children with primary nephrotic syndrome (NS). Methods: Case control study. The case group included 7 children aged 1 to 18 years with NS combined with AC hospitalized in Peking University First Hospital from January 2016 to May 2021 (AC group). According to the ratio of case group: control group 1: 4, 28 children aged 1 to 18 years who were diagnosed with NS without AC during the same period were matched as controls (non-AC group). Clinical data were collected. The clinical characteristics of AC were described. The clinical parameters were compared between the 2 groups by t test, Mann-Whitney U test or Fisher's test. Receiver operating characteristic (ROC) curve was used to analyze the cutoff values of clinical parameters for prediction of AC. Results: The AC group included 4 boys and 3 girls aged 6.9 (4.6, 10.8) years. The non-AC group included 20 boys and 8 girls aged 5.2 (3.3, 8.4) years. All AC events occurred during the relapse of NS with infection. Seven children had gastrointestinal symptoms such as nausea, vomiting and abdominal pain. Six children had poor mental state or impaired consciousness. No significant differences in NS course, corticosteroid treatment course, corticosteroid type, steroid dosage, steroid medication interval, the proportion of gastroenteritis and fever existed between the two groups (all P>0.05). Compared with the non-AC group, the duration from the onset of the relapse of NS until hospitalization in the AC group was significantly shorter (0.2 (0.1, 0.6) vs. 1.0 (0.4, 5.0) month,U=25.50, P=0.005). The 24 h urinary total protein (UTP) level was significantly higher in the AC group (193 (135, 429) vs. 81 (17, 200) mg/kg, U=27.00,P=0.036) than the non-AC group. The serum albumin level in the AC group was significantly lower((13.1±2.1) vs. (24.5±8.7) g/L,t=-6.22,P<0.001) than the non-AC group. There were significantly higher total white blood cell counts ((26±9)×109 vs. (11±5)×109/L,t=4.26,P=0.004), percentage of neutrophils (0.71±0.08 vs. 0.60±0.19,t=2.56,P=0.017) and the proportion of children with C reactive protein level≥8 mg/L (3/7 vs. 0,P=0.005) in the AC group than in the non-AC group. ROC curve analysis showed that the cutoff value of 24 h UTP was 122 mg/(kg·d) with a sensitivity of 100.0% and specificity of 70.4%. The cutoff value of serum albumin was 17.0 g/L with a sensitivity of 100.0% and specificity of 82.1%. Conclusions: Gastrointestinal symptoms and poor mental state were prominent manifestations of AC in children with NS. High 24 h UTP level, low serum albumin level, high peripheral white blood cell counts, high neutrophils percentage, and high C-reactive protein level during the early stage of NS relapse may be related to the occurrence of AC in children with NS.
Nephrotic Syndrome/drug therapy*
;
Humans
;
Child
;
Adolescent
;
Male
;
Female
;
Gastrointestinal Diseases/diagnosis*
;
Adrenal Cortex Hormones/therapeutic use*
;
Nausea/chemically induced*
;
Vomiting/chemically induced*
;
Abdominal Pain/chemically induced*
;
Mental Processes/drug effects*
;
China
6.The role of opioids in managing chronic non-cancer pain.
Ban Leong SNG ; Stephan Alexander SCHUG
Annals of the Academy of Medicine, Singapore 2009;38(11):960-966
The use of opioids for the treatment of chronic non-cancer pain has become more widespread recently. Available data support the short-term use of opioids in clearly defined nociceptive and neuropathic pain states. Their use in 'pathological' pain states without a clear diagnosis, such as chronic low back pain, is more contentious. A decision to initiate opioid treatment in these conditions requires careful consideration of benefits and risks; the latter include not only commonly considered adverse effects such as constipation, but also opioid-induced hyperalgesia, abuse, addiction and diversion. Ideally, treatment goals should not only be relief of pain, but also improvement of function. Opioid treatment of chronic non-cancer pain requires informed consent by, and preferably a treatment contract with, the patient. Treatment should be initiated by a trial period with defined endpoints using slow-release or transdermal opioids. Ongoing management of the patient requires ideally a multi-disciplinary setting. Treatment should not be regarded as life-long and can be discontinued by tapering the dose.
Analgesics, Opioid
;
adverse effects
;
therapeutic use
;
Humans
;
Hyperalgesia
;
chemically induced
;
Low Back Pain
;
drug therapy
;
Pain, Intractable
;
drug therapy
;
Substance-Related Disorders
;
prevention & control
7.Adverse effects of combining polyethylene glycol interferon with ribavilin on hepatitis C patients.
Chinese Journal of Hepatology 2003;11(11):686-687
Antiviral Agents
;
adverse effects
;
therapeutic use
;
Drug Therapy, Combination
;
Fatigue
;
chemically induced
;
Fever
;
chemically induced
;
Headache
;
chemically induced
;
Hepatitis C
;
drug therapy
;
Humans
;
Interferon-alpha
;
adverse effects
;
therapeutic use
;
Pain
;
chemically induced
;
Polyethylene Glycols
;
chemistry
;
Recombinant Proteins
;
Ribavirin
;
adverse effects
;
therapeutic use
8.Factors Predictive of Treatment-Emergent Adverse Events of Prucalopride: An Integrated Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials.
Somchai LEELAKUSOLVONG ; Meiyun KE ; Duowu ZOU ; Suck Chei CHOI ; Jan TACK ; Eamonn M M QUIGLEY ; Andy LIU ; Jinyong KIM
Gut and Liver 2015;9(2):208-213
BACKGROUND/AIMS: This integrated analysis aimed to identify the factors associated with the most frequently reported treatment-emergent adverse events (TEAEs) in Asian and non-Asian patients with chronic constipation (CC) who receive prucalopride or placebo over 12 weeks. METHODS: Pooled data from four randomized, double-blind, placebo-controlled, multicenter, phase III studies (NCT00488137, NCT00483886, NCT00485940, and NCT01116206) on patients treated with prucalopride 2 mg or placebo were analyzed. The associations between predictors and TEAEs were evaluated based on a logistic regression model. RESULTS: Overall, 1,821 patients (Asian, 26.1%; non-Asian, 73.9%) were analyzed. Prucalopride treatment was significantly associated with diarrhea, headache, and nausea (p<0.001), but not with abdominal pain, compared with placebo. Differences in the prevalence of TEAEs between prucalopride and placebo decreased greatly after the first day of treatment. Compared with non-Asians, Asians were more likely to experience diarrhea and less likely to develop abdominal pain, headache, and nausea. Prior laxative use, CC duration, and body weight were not predictive of any of these TEAEs. CONCLUSIONS: Prucalopride treatment was positively associated with diarrhea, headache, and nausea. Asian patients tended to have a higher frequency of diarrhea but lower frequencies of headache, abdominal pain, and nausea compared with non-Asians.
Abdominal Pain/*chemically induced
;
Adult
;
Aged
;
Aged, 80 and over
;
Asian Continental Ancestry Group/statistics & numerical data
;
Benzofurans/*adverse effects
;
Clinical Trials, Phase III as Topic
;
Constipation/*drug therapy/ethnology
;
Diarrhea/*chemically induced
;
Double-Blind Method
;
Female
;
Headache/*chemically induced
;
Humans
;
Male
;
Middle Aged
;
Multicenter Studies as Topic
;
Nausea/chemically induced
;
Randomized Controlled Trials as Topic
;
Regression Analysis
9.Factors Predictive of Treatment-Emergent Adverse Events of Prucalopride: An Integrated Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials.
Somchai LEELAKUSOLVONG ; Meiyun KE ; Duowu ZOU ; Suck Chei CHOI ; Jan TACK ; Eamonn M M QUIGLEY ; Andy LIU ; Jinyong KIM
Gut and Liver 2015;9(2):208-213
BACKGROUND/AIMS: This integrated analysis aimed to identify the factors associated with the most frequently reported treatment-emergent adverse events (TEAEs) in Asian and non-Asian patients with chronic constipation (CC) who receive prucalopride or placebo over 12 weeks. METHODS: Pooled data from four randomized, double-blind, placebo-controlled, multicenter, phase III studies (NCT00488137, NCT00483886, NCT00485940, and NCT01116206) on patients treated with prucalopride 2 mg or placebo were analyzed. The associations between predictors and TEAEs were evaluated based on a logistic regression model. RESULTS: Overall, 1,821 patients (Asian, 26.1%; non-Asian, 73.9%) were analyzed. Prucalopride treatment was significantly associated with diarrhea, headache, and nausea (p<0.001), but not with abdominal pain, compared with placebo. Differences in the prevalence of TEAEs between prucalopride and placebo decreased greatly after the first day of treatment. Compared with non-Asians, Asians were more likely to experience diarrhea and less likely to develop abdominal pain, headache, and nausea. Prior laxative use, CC duration, and body weight were not predictive of any of these TEAEs. CONCLUSIONS: Prucalopride treatment was positively associated with diarrhea, headache, and nausea. Asian patients tended to have a higher frequency of diarrhea but lower frequencies of headache, abdominal pain, and nausea compared with non-Asians.
Abdominal Pain/*chemically induced
;
Adult
;
Aged
;
Aged, 80 and over
;
Asian Continental Ancestry Group/statistics & numerical data
;
Benzofurans/*adverse effects
;
Clinical Trials, Phase III as Topic
;
Constipation/*drug therapy/ethnology
;
Diarrhea/*chemically induced
;
Double-Blind Method
;
Female
;
Headache/*chemically induced
;
Humans
;
Male
;
Middle Aged
;
Multicenter Studies as Topic
;
Nausea/chemically induced
;
Randomized Controlled Trials as Topic
;
Regression Analysis
10.Patient-controlled intravenous analgesia with sufentanil and fentanyl after thoracotomy: a comparative study.
Chun-shui LIN ; Gang LU ; Luo-yang RUAN ; Miao-ning GU
Journal of Southern Medical University 2006;26(2):240-244
OBJECTIVETo evaluate the clinical efficacy of sufentanil and fentanyl at equivalent dose for patient-controlled intravenous analgesia (PCIA) after thoracotomy.
METHODSSixty ASA I-II patients (20-60 years of age) undergoing radical operation for lung or esophageal cancer were randomly divided into sufentanil intravenous analgesia group (group S, with sufentanil 1 microg/ml) and fentanyl intravenous analgesia group (group F, fentanyl 10 microg/ml). PCIA was administered with background infusion of 2.5 ml/h, bolus injection of 2.5 ml and lockout time of 15 min. The pain intensity according to visual analogue scale (VAS), cumulative analgesic consumption (CAC), sedative scores and side effects at 24 and 48 h after administration were recorded. SpO(2), respiratory rate (RR), blood pressure (BP) and ECG were continuously monitored.
RESULTSThere were no significant differences in CAC between the two groups, but he VAS was lower in group S than in group F (P<0.05) and the sedative efficacy was superior in group S (P<0.05). The incidence of nausea and vomiting in group S was lower than that in group F (P<0.05). No significant differences were observed in SpO(2), RR, heart rate and mean arterial pressure between the two groups.
CONCLUSIONPCIA with sufentanil provides better efficacy of analgesia and sedation with lower incidence of nausea and vomiting than with fentanyl in postoperative patients with thoracotomy.
Adult ; Analgesia, Patient-Controlled ; Esophageal Neoplasms ; surgery ; Female ; Fentanyl ; administration & dosage ; adverse effects ; Humans ; Infusions, Intravenous ; Lung Neoplasms ; surgery ; Male ; Middle Aged ; Nausea ; chemically induced ; Pain, Postoperative ; drug therapy ; Sufentanil ; administration & dosage ; adverse effects ; Thoracotomy ; Vomiting ; chemically induced